WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO) (“Encorium”), a leader in the design and management of complex clinical trials and patient disease registries for the pharmaceutical, biotechnology and medical device industries, today announced the signing of a multi-year contract valued at approximately $12.4 million for the conduct of a Phase 3 trial in prostate cancer. T
